An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma
NCT03968315 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2026-03-09
Summary
This trial studies the accuracy of a magnetic resonance imaging (MRI) scan in imaging the inside of the chest in patients with thymoma that is newly diagnosed or has come back. An MRI scan may be able to detect if and how far the tumor has spread more accurately than a standard computed tomography (CT) scan.
Conditions
- Recurrent Malignant Thymoma
- Thymoma
Interventions
- PROCEDURE
-
Diaphragm Fluoroscopy
Undergo diaphragm fluoroscopy
- PROCEDURE
-
Magnetic Resonance Imaging
Undergo MRI
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
M.D. Anderson Cancer Center
lead OTHER
Principal Investigators
-
Marcelo F Benveniste · M.D. Anderson Cancer Center
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-06-08
- Primary Completion
- 2029-04-30
- Completion
- 2029-04-30
Countries
- United States
Study Locations
More Related Trials
-
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
NCT00036855 ·Status: TERMINATED ·Phase: PHASE1
-
Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma
NCT00645359 ·Status: TERMINATED
-
Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas
NCT00685997 ·Status: COMPLETED
-
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
NCT02051257 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
NCT03493451 ·Status: COMPLETED ·Phase: PHASE2
-
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma
NCT00003337 ·Status: UNKNOWN ·Phase: PHASE3
-
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00005592 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
NCT03927105 ·Status: COMPLETED ·Phase: PHASE2
-
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
NCT04083495 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
NCT00088881 ·Status: TERMINATED ·Phase: PHASE2
-
Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma
NCT00378768 ·Status: COMPLETED ·Phase: PHASE2
-
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
NCT03019640 ·Status: COMPLETED ·Phase: PHASE2
-
Minimal Residual Disease in Peripheral T-cell Lymphoma
NCT03297697 ·Status: COMPLETED
-
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
NCT03921671 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
NCT04526834 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
NCT00008021 ·Status: UNKNOWN ·Phase: PHASE1
-
Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy
NCT04870853 ·Status: RECRUITING
-
Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients
NCT03850028 ·Status: WITHDRAWN ·Phase: NA
-
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
NCT00070447 ·Status: COMPLETED ·Phase: PHASE2
-
A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission
NCT05874778 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy
NCT04745949 ·Status: RECRUITING ·Phase: PHASE2
-
Immunotherapy in Lymphoma
NCT06796517 ·Status: RECRUITING
-
Amifostine for Head and Neck Irradiation in Lymphoma
NCT00136474 ·Status: COMPLETED ·Phase: PHASE2
-
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
NCT02690545 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
NCT00438880 ·Status: COMPLETED ·Phase: PHASE1/PHASE2